Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma.

Abstract

Among 199 patients treated with thalidomide for multiple myeloma, four thromboses occurred in 49 cases during erythropoietin therapy (prevalence 8.1%; annual rate 7.25%), and another 14 events occurred in patients not on erythropoietin (9.3%; 7.56%). Thus, erythropoietin would seem not to increase the risk of thrombosis of myeloma patients receiving thalidomide.

• Authors: Monica Galli, Francesca Elice, Claudia Crippa, Benedetto Comotti, Francesco Rodeghiero, Tiziano Barbui
• Journal: Haematologica (Haematologica) Vol. 89 Issue 9 Pg. 1141-2 (Sep 2004) ISSN: 1592-8721 [Electronic] Italy
• PMID: 15377478 (Publication Type: Letter)

Chemical References

• Anticoagulants
• Antineoplastic Agents
• Recombinant Proteins
• Erythropoietin
• Thalidomide
• Warfarin

Topics

• Adult
• Aged
• Aged, 80 and over
• Anticoagulants (therapeutic use)
• Antineoplastic Agents (adverse effects, pharmacology, therapeutic use)
• Drug Synergism
• Erythropoietin (adverse effects, pharmacology, therapeutic use)
• Female
• Humans
• Male
• Middle Aged
• Multiple Myeloma (complications, drug therapy)
• Recombinant Proteins
• Risk
• Thalidomide (adverse effects, pharmacology, therapeutic use)
• Thrombosis (chemically induced, epidemiology, etiology, prevention & control)
• Venous Thrombosis (chemically induced, epidemiology, etiology, prevention & control)
• Warfarin (therapeutic use)